Mitochondrial transplantation: human studies and Mitrix Bio

Longevitytech.fund portfolio · Mitrix Bio

Longevitytech.fund is an investor in Mitrix Bio. We are proud to support its work on mitochondrial therapies and the prospect of restoring function in damaged tissues. [14]

What has been shown—and what remains open

• Shown: researchers have transferred mitochondria into people during serious heart and stroke care. Small studies have reported encouraging functional findings or preliminary tolerability observations.[2] [3] [4]

• Not shown: dependable benefits or well-characterized long-term risks for mitochondrial infusions intended to treat aging. A fertility application also missed its primary outcome despite changes in some early biological measurements.[7] [9] [10] [11]

• What would change the assessment: controlled results for a clearly identified preparation and route, with meaningful patient outcomes and enough follow-up to assess durability and harm.

The evidence and program descriptions below are dated September 22, 2026. “Mitochondrial transplantation” describes several procedures, with different materials and destinations. A result for one does not establish the effect of another.

Which mitochondria, delivered where?

Mitochondria help cells turn nutrients into usable energy and perform other tasks. Their function can be disrupted when blood supply stops, as in a heart attack or an ischemic stroke. Researchers are testing whether supplying functioning mitochondria can help injured tissue recover.[2] [3] [4]

Autologous means the material comes from the person receiving it; donor-derived means it comes from someone else. Preparations may use mitochondria isolated from a small muscle sample, mitochondria obtained from platelets, or mitochondria carried in membrane-bound particles. Platelets are blood components involved in clotting. Delivery may be directly into a tissue, through an artery supplying it, or by an infusion intended to circulate more broadly.[1] [2] [3] [4] [7] [8] [9] [10]

A 2025 scientific consensus statement proposed clearer terminology because natural transfer between cells, transplantation of isolated mitochondria and cell engineering are often discussed together. The first useful question is therefore what, exactly, was transferred and where it went.[1]

The human studies differ substantially

Children receiving heart-lung support

The children had severe heart dysfunction after cardiac surgery, compromised coronary blood flow and subsequent restoration of that flow. They needed extracorporeal membrane oxygenation, or ECMO, a machine that supports circulation and oxygen delivery. The 8-of-10 versus 4-of-14 result concerned successful separation from ECMO without needing it restarted within a week.[2]

That is a promising association in a critical situation. The study was small, from one center, and looked back at care delivered between 2002 and 2018. Treatment was not randomly assigned. Differences in patients, decisions about treatment and changes in care over those years could influence the result. It does not establish a benefit for generally healthy older people receiving an infusion.[2]

A randomized heart-attack trial

The 2024 trial involved 30 adults with an acute ST-elevation myocardial infarction, a type of heart attack with a characteristic pattern on a recording of the heart’s electrical activity. The authors described it as a randomized, triple-blind trial, with treatment assignments concealed to reduce bias. They reported greater exercise capacity and a small additional improvement in left ventricular ejection fraction—the proportion of blood pumped out of the heart's main pumping chamber with each contraction.[3]

Random allocation makes this a stronger test than an uncontrolled series. Its 40-day follow-up and 15 people per group leave the durability of recovery and uncommon risks unresolved. No statistically significant difference in monitored adverse events means the study did not detect a difference; it does not demonstrate equivalent safety. The functional signal warrants further testing without establishing routine cardiac care.[3]

Four people treated during stroke care

The stroke report concerned adults aged 43–80 receiving mechanical thrombectomy, a procedure to remove a clot from a brain artery. Fresh mitochondria from each person's own skeletal muscle were delivered through a catheter alongside that standard treatment. Short-term observations, including monitoring of effects throughout the body up to seven days, identified none of the prespecified adverse events in those four patients.[4]

The investigators compared safety observations with previously treated patients selected for similar characteristics. They did not have a randomized control group treated at the same time. Restoring blood flow through clot removal can itself improve recovery, so any recovery cannot be attributed to the added mitochondria. This was a feasibility and early safety report, first published online on December 4, 2024, then assigned to a February 2026 journal issue.[4]

Two US trial records give additional dated context. The stroke record, NCT04998357, listed an estimated 20 participants and a recruiting status in its May 21, 2025 update. The pediatric cardiac record, NCT02851758, listed an estimated 16 and recruiting in its January 5, 2026 update. Those figures describe the registry studies; the cardiac estimate is separate from the published 24-child retrospective comparison. Neither record contained a posted results dataset as of September 22, 2026. Published papers can exist without results posted in a registry, and an older recruiting label does not confirm a place is available now.[5] [6]

A biological change can accompany a disappointing outcome

The 2026 fertility trial is a useful counterweight to an exclusively positive account. It enrolled women aged 21–42 with at least two unsuccessful assisted-reproduction cycles. Eggs from each woman were randomly assigned to receive mitochondria from her own bone-marrow-derived stem cells during fertilization, or to standard fertilization alone. Both groups used intracytoplasmic sperm injection (ICSI), in which a single sperm is injected into an egg.[11]

Some early divisions happened sooner after supplementation. Yet the primary, or main planned, outcome—the rate of good-quality embryos on day 3—did not improve. The proportion of normally fertilized eggs that went on to divide was lower with supplementation. Faster timing for one stage therefore did not translate into the intended embryo-quality benefit.[11]

The report also found no pregnancy or live-birth advantage. Those later comparisons were not randomized at the woman level: embryo selection could influence which women received embryos from each group. They cannot establish a causal effect on live birth.[11]

This application differs from emergency heart treatment and systemic infusion. Its results do not settle the value of every mitochondrial approach. They show why each needs to succeed on the outcome that matters to the person receiving it.

What Mitrix announced

Mitrix Bio's descriptions concern another set of preparations, including broader delivery and a proposed personal bioreactor platform. A bioreactor is a system for growing biological material under controlled conditions. These company announcements are separate from the published studies above.

On April 6, 2026, Mitrix announced what it called completion of preliminary phase 1 safety trials. It named participants aged 71 and 91 and described escalating infusions beginning in February, with blood chemistry and physical monitoring. The company reported no obvious adverse effects and said results would be shared with selected hospitals and researchers. The release did not provide a complete public clinical report, comparator or registry identifier.[7]

A later company announcement described this earlier work as involving two volunteers. That is a very small basis for a safety claim, particularly when the full follow-up and adverse-event details are not supplied. Calling work “phase 1” does not establish that the exact preparation is ready for broader use.[7] [9]

A second April 6 release announced experimental clinics in Newport Beach, Dallas and Palm Beach, referring to “Right to Try 2.0” or other regulatory guidance. It also described the treatments as unproven and experimental. This is an announcement of intended access, not a demonstration of efficacy or authorization for every proposed use.[8]

The later program descriptions must also remain distinct:

• The personal-bioreactor project proposed an initial group of 10 volunteers and production of material derived from the recipient. That planned group is separate from the two-person earlier account. The PDF is dated June 16, 2026, although the company news index groups it under August.[9]

• The August 16, 2026 MITO-FIX announcement described a Calgary collaboration using platelet-derived mitochondrial vesicles called Mitlets—membrane-bound particles—for research involving mitochondrial diseases and severe infections. It said authorities had not yet determined whether the regulatory framework it cited covered the proposed work. This is different material from the proposed personal-bioreactor preparation.[10]

The next useful milestone is a complete clinical report showing how participants’ symptoms or physical function changed, alongside adverse events and follow-up. Mitrix's website disclaimer also states that the trials or treatments it describes have not received approval or authorization from the US Food and Drug Administration (FDA). This is an attributed company statement; documentation for each particular program remains essential.[13]

Access and approval are separate from benefit

Under the US federal Right to Try pathway described by FDA, eligible patients have a life-threatening condition, have exhausted approved options and cannot participate in a relevant clinical trial. The drug has separate eligibility requirements. Completing a phase 1 trial is only one of them.[12]

FDA also describes requirements concerning an approval application or a qualifying investigation under an active investigational new drug application, continuing development, and absence of a clinical hold—an order delaying or suspending a clinical trial. FDA does not review or approve individual federal Right to Try requests. Access through that pathway is distinct from product approval.[12]

The federal explanation should not be substituted for a company's reference to a state “2.0” pathway. Whether a particular product and intended use meet applicable requirements depends on documentation for that product and program. A clinic announcement alone cannot resolve the evidence of benefit, legal and ethical oversight, or eligibility to join a specific study.

How Healthy Longevity Clinic experts evaluate the evidence

Healthy Longevity Clinic sees a concrete healthspan reason to follow mitochondrial transplantation: helping people recover organ function and physical capacity after serious injury. The cardiac studies make that possibility clinically interesting, with early recovery and exercise findings that deserve larger, longer comparisons. [2] [3]

Mitrix Bio brings a separate development approach to this field. For its infusion and bioreactor programs, we would look for sustained changes in daily activity, fatigue, mobility or disease burden, measured against appropriate care. The material, delivery route and patient group must be specified so that the result answers a practical clinical question.

Longevitytech.fund’s investment makes this research a connection we are proud to highlight. The next advance that would strengthen the clinical case is a complete, controlled report with reproducible preparation, meaningful functional outcomes and adverse-event follow-up, including after repeat treatment.

Three questions to bring to a clinical conversation

1. What is the exact mitochondrial source, preparation and delivery route, and which published study used it in people with my condition?

2. What protocol or registry identifier, oversight and eligibility rules apply to this particular program?

3. How will benefit and adverse events be measured, reported and followed over time, including after any repeated treatment?

Common questions

Has this been tested in people, or only in animals?

It has reached human studies, including a small randomized heart-attack trial. The preparation, patient group and outcome remain essential: human testing in one setting does not validate all uses.[2] [3] [4] [11]

Does no observed adverse effect mean the treatment is safe?

It provides information about the people observed and the time covered. Very small studies can miss rare or delayed harms, and a nonsignificant safety comparison does not establish that two treatments are equally safe.[3] [4]

Does a recruiting registry entry mean I can receive it?

A dated registry entry describes a study's submitted status. Eligibility, active recruitment and a specific place must be established with that study; the old status alone confirms none of them.[5] [6]